Graft vs Host Disease Treatment Market: Global Estimation, Dynamics, Regional Share, Trends, Competitor Analysis 2017 to 2021 and Forecast 2022 to 2028

Description

Graft vs Host Disease Treatment Market size was valued at USD 2,967.9 million in 2021, growing at a CAGR of 8.1% during the forecast period 2022 to 2028. The global market provides a detailed overview of the market, and that can be segmented by Drug Class, Disease Type, by Route of Administration, and by Distribution Channel. By drug class, the global Graft vs Host Disease Treatment market has been segmented into Monoclonal Antibodies, Immunosuppressive Drugs, Steroids, TNF Inhibitorso, Tyrosine Kinase Inhibitors, Others. The monoclonal antibodies segment is likely to be the largest and fastest-growing segment in terms of drug class. Based on Disease Type, the global Graft vs Host Disease Treatment market is segmented into Acute Graft vs Host Disease, Chronic Graft vs Host Disease. Among these, the Acute Graft vs Host Disease segment is expected to have the fastest-growing segment during the forecast period 2022-2028. Based on route of administration, the global Graft vs Host Disease Treatment market is segmented into Oral, Parenteral. The oral segment accounts for the largest share in 2021. Based on the distribution channel, the segment has been segregated into Hospital Pharmacies, Retail Pharmacies Online Pharmacies. The hospital pharmacies segment is expected to dominate other segments in the global market. The retail pharmacies segment is expected to witness the highest CAGR during the forecast period according to precision business insights.

Key Development:

In Sept 2021, Ruxolitinib has been approved by the US Food and Drug Administration (FDA) for the treatment of chronic Graft-versus-Host disease in patients 12 years of age and older who have failed any two conventional therapies.

In May 2022, Jakavi  ruxolitinib) from Novartis has been given European Commission (EC) approval for the treatment of patients with acute or chronic GvHD who have had a poor response to corticosteroids or other systemic treatments and are 12 years of age or older.